1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.

  2. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci  USA 1989;86:9412-9416.

  3. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966;25(6 Suppl):623-626.

  4. Becker MA, Schumacher HR, Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.

  5. Wu XW, Muzny DM, Lee CC, Caskey CT. Two
 independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.

  6. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link? J Am Soc Nephrol 2005;16:1909-1919.

  7. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005;25:3-8.

  8. Mazzali M, Kanbay M, Segal MS, et al. Uric acid 
and hypertension: cause or effect? Curr Rheumatol Rep 2010;12:108-117.

  9. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly 
diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-932.

  10. Shin HJ, Takeda M, Enomoto A, et al. Interactions 
of urate transporter URAT1 in human kidney 
with uricosuric drugs. Nephrology (Carlton) 2011;16:156-162.

  11. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate 
transporter 1 (URAT 1) in hypertensive patients. 
Am J Hypertens 2008;21:1157-1162.

  12. Hamada T, Mizuta E, Kondo T, et al. Effects of a 
low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung 2010;60:71-75.

  13. Mima A, Ichida K, Matsubara T, et al. Acute 
renal failure after exercise in a Japanese sumo wrestler with renal hypouricemia. Am J Med Sci 2008;336:512-514.

  14. Ichida K, Hosoyamada M, Hisatome I, et al. 
Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004;15:164-173.

  15. Wu AH, Ghali JK, Neuberg GW, et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010;160:928-933.

  16. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-108.

  17. Bleyer AJ, Trachtman H, Sandhu J, et al. Renal manifestations of a mutation in the uromodulin (Tamm Horsfall protein) gene. Am J Kidney Dis 2003;42:E20-26.

  18. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-289.

  19. Choi HK, Curhan G. Alcohol and gout. Am J Med 2007;120:e5.

  20. Choi HK, Curhan G. Beer, liquor, and wine 
consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004;51:1023-1029.

  21. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent 
developments in diet and gout. Curr Opin 
Rheumatol 2006;18:193-198.

  22. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000;11:974-979.

  23. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005;80:1383-1391.

  24. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-613.

  25. Schlesinger N, Detry MA, Holland BK, et al. Local 
ice therapy during bouts of acute gouty arthritis. 
J Rheumatol 2002;29:331-334.

  26. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-1068.

  27. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyper-uricemic therapy. Arthritis Rheum 2004;51:321-325.

  28. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009;21:143-149.

  29. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-de la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005;331:623-624.

  30. Casas E, Puig JG, Mateos FA, et al. The 
allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels. Adv Exp Med Biol 1989;253A:257-260.

  31. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-1282.

  32. Schumacher HR, Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-1548.

  33. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.

  34. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-1393.

  35. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. 
Am J Kidney Dis 2006;47:51-59.